Capoten ANDA approvals would render Waxman/Hatch 3-year exclusivity "largely meaningless" -- Bristol suit.
Executive Summary
CAPOTEN ANDA APPROVALS WOULD MAKE WAXMAN/HATCH EXCLUSIVITY "MEANINGLESS," Bristol-Myers Squibb maintains in a recent court filing in a civil case challenging FDA's implementation of the Waxman/Hatch three-year exclusivity provisions for new indications. The suit points out that state and private formularies often encourage or require the substitution of an "AB"-rated generic when one is available without regard to indication. Those substitutions render "any patent protection or non-patent exclusivity rights covering the supplemental indication largely meaningless," Bristol declares.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth